The Quantellect read.As of Nov 19, 2026, 4 active firms cover Contineum Therapeutics, Inc. Class A Common Stock: 2 rate it Buy or better, 2 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. Targets range widely, $14.00 to $30.00 (about 2.1x), a sign of real disagreement on valuation. The average target of $21.00 sits 127% above the current $9.25. The rating mix has stayed broadly stable, with Buy-side ratings easing from 3 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.47 next quarter toward $-2.05 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 active firms
Neutral
Strong Buy00%
Buy250%
Neutral250%
Sell00%
Strong Sell00%
Based on 4 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$21.00
+127.0% upside
Average target across 4 active firms as of Nov 19, 2026 vs $9.25 current
Highest Target$30.00
Average Target$21.00
Lowest Target$14.00
Detailed analyst forecasts for CTNM
Showing 1–4 of 4 named analysts shown · 4 active firms in the rating projection
As of Nov 19, 2026, 2 of 4 active firms rate CTNM a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CTNM EPS & revenue forecast
EPS · NEXT QUARTER
$-0.47
Range $-0.54 – $-0.39 · 3 analysts · +21% YoY
Next period, 3 analysts expect Contineum Therapeutics, Inc. Class A Common Stock to earn $-0.47 a share (range $-0.54 – $-0.39), versus $-0.39 a year earlier. Full-year consensus is $-1.78, growing to $-2.05 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Contineum Therapeutics, Inc. Class A Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CTNM.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #10
Neutral
$17.00+83.8% to target
Overall win rate
64%
+ Follow
#2
Joel Beatty
Baird · Rank #71
Neutral
$14.00+51.4% to target
Overall win rate
50%
+ Follow
#3
Brian Abrahams
RBC Capital · Rank #502
Buy
$21.00+127.0% to target
Overall win rate
26%
+ Follow
#4
MM
Myles Minter
William Blair
Buy
No targeton CTNM
Coverage
—
+ Follow
#5
DC
Debanjana Chatterjee
Jones Trading
Buy
$30.00+224.3% to target
Coverage
—
+ Follow
CTNM stock forecast FAQ
What is CTNM's average 12-month price target?+
The 4 active firms with a live target average $21.00 for Contineum Therapeutics, Inc. Class A Common Stock over the next 12 months, ranging from a $30.00 high to a $14.00 low, as of Nov 19, 2026.
Is CTNM stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 4 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 2 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CTNM?+
The Street-high target is $30.00 (Jones Trading), and the Street-low is $14.00 (Baird). The average of all 4 active-firm targets is $21.00.
How many active Wall Street firms cover CTNM?+
4 active firms have a recognized rating on Contineum Therapeutics, Inc. Class A Common Stock as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CTNM?+
Among analysts who currently cover CTNM, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #10). Their current call is Neutral with a $17.00 target.
What is Contineum Therapeutics, Inc. Class A Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.47 per share (range $-0.54 – $-0.39) across 3 analysts. Full-year EPS is projected at $-1.78, rising to $-2.05 the following year.
How much revenue is Contineum Therapeutics, Inc. Class A Common Stock expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading CTNM lately?+
As of Nov 19, 2026, 2 of 4 active firms rate CTNM a Buy (2 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CTNM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.